MoonLake Immunotherapeutics

MLTX · NASDAQ

$10.32+$0.57 (+5.85%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $9.75

About MLTX

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 130 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Employees: 130
Headquarters: Zug, Zug
Listed: Oct 20, 2020
Sector: Health Care
Industry: Biotechnology
Website: moonlaketx.com

Leadership

MoonLake Immunotherapeutics executives
Name	Title	Since	Age
Jorge Santos Da Silva	—	2022	48
Simon Sturge	—	—	66
Matthias Bodenstedt	—	—	35
Kristian Reich	—	—	57
Spike Loy	—	—	44
Catherine Moukheibir	—	—	66
Andrew Phillips	—	—	52
Ramnik Xavier	—	—	61
Atif Khan	—	2023	—

Similar companies

Companies in the same industry as MoonLake Immunotherapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.